Studies with patient-derived CRC xenografts have reproduced and confirmed the clinical resistance or sensitivity to cetuximab therapy according to KRAS mutation status that was observed in clinical trials [9], and selection of chemotherapy-resistant clones has also been observed in CRC xenografts [10]. Here, KRAS is linked to colorectal carcinoma.